79 BALONNE ST, NARRABRI. 2390

Phone: 0473925904

Birthdate: 10/09/1998 Sex: M Medicare Number: 2457747468

Your Reference: 00072079 Lab Reference: 23-24481926-FBE-0

Laboratory: Laverty Pathology

Addressee: DR JULIAN WHITE Referred by: DR JULIAN WHITE

Name of Test: HAEMATOLOGY (FBE-0)

Requested: 04/10/2023 Collected: 04/10/2023 Reported: 04/10/2023

22:48

HAEMATOLOGY

Date Collected 04 Oct 23
Time Collected 12:36
Specimen Type: EDTA

Specimen Type: EDTA

Hb	172	g/L	(130-180)	WBC	5.5 x	10^9 /	'L (4,0-11.0)
RCC	5.7	x10^12	/L (4.5-6.5)				/L (2.0-7.5)
Hct	0.51		(0.40-0.54)				/L (1.0-4.0)
MCV	89	fL	(79-99)	Mono	0.3	x10^9	/L (0.2-1.0)
MCH	30	pg	(27-34)	Eos	0.1	x10^9	/L (< 0.7)
MCHC	338	g/L	(320-360)	Baso	0.0	x10^9	/L (< 0.2)
RDW	12.3	용	(10.0-17.0)				1/2
Plat	241	x10^9	/L (150-400)				

HAEMATOLOGY: FBC parameters are within reference range.

Requested Tests: VBF*, TFT*, MBA*, LIP*, FE*, FBE, A1C*

79 BALONNE ST, NARRABRI. 2390

Phone: 0473925904

Birthdate: 10/09/1998 Sex: M Medicare Number: 2457747468

Your Reference: 00072079 Lab Reference: 23-24481926-TFT-0

Laboratory: Laverty Pathology

Addressee: DR JULIAN WHITE Referred by: DR JULIAN WHITE

Name of Test: THYROID FUNCTION TEST (TFT-0)

Requested: 04/10/2023 **Collected:** 04/10/2023 **Reported:** 04/10/2023

23:15

THYROID PROFILE

Specimen Type: Serum

1.5 mIU/L (0.5-4.0) TSH

Result(s) consistent with euthyroidism.

Requested Tests : VBF*, TFT, MBA*, LIP*, FE*, FBE, A1C*

79 BALONNE ST, NARRABRI. 2390

Phone: 0473925904 Birthdate: 10/09/1998 Sex: M Medicare Number: 2457747468 **Your Reference:** 00072079 **Lab Reference:** 23-24481926-MBA-0

Laboratory: Laverty Pathology

Addressee: DR JULIAN WHITE Referred by: DR JULIAN WHITE

Name of Test: SERUM CHEMISTRY (MBA-0)

Requested: 04/10/2023 **Collected:** 04/10/2023 **Reported:** 04/10/2023

23:19

Specimen Type: Serum	SERUM CHE	EMISTRY	
Haemolysis	Nil		
Icterus	Nil		
Lipaemia	Nil		
	MIT		
Sodium	136	mmol/L	(135-145)
Potassium	4.4	mmol/L	(3.6-5.4)
Chloride	97	mmol/L	(95-110)
Bicarbonate	21	mmol/L	(22-32)
Anion Gap	22	mmol/L	(10-20)
Urea	4.1	mmol/L	(2.5-7.5)
Creatinine	75	umol/L	(60-110)
eGFR	> 90		mL/min/1.73m^2
Bilirubin	15	umol/L	(< 20)
AST	36	U/L	(< 35)
ALT	33	U/L	(< 40)
GGT	31	U/L	(< 40)
Alkaline Phosphatase	126	U/L	(35-110)
Protein	84	g/L	(60-82)
Albumin	51	q/L	(38-50)
Globulin	33	g/L	(20-38)
	33	9/11	(20-36)

eGFR \geq =90 mL/min/1.73m2 usually indicates normal kidney function but does not exclude patients with early kidney damage (those with albuminuria, haematuria or abnormal kidney imaging).

Requested Tests : VBF*, TFT, MBA, LIP, FE, FBE, A1C*

79 BALONNE ST, NARRABRI. 2390

Phone: 0473925904

Birthdate: 10/09/1998 Sex: M Medicare Number: 2457747468

Your Reference: 00072079 Lab Reference: 23-24481926-FE-0

Laboratory: Laverty Pathology

Addressee: DR JULIAN WHITE Referred by: DR JULIAN WHITE

Name of Test: IRON STUDIES (FE-0)

Requested: 04/10/2023 Collected: 04/10/2023 Reported: 04/10/2023

23:19

IRON STUDIES

Specimen Type: Serum			
Serum Iron	17	umol/L	(10-30)
Transferrin	33	umol/L	(27-46)
Transferrin Saturation	26	9	(13-45)
Serum Ferritin	77	ua/L	(30-300)

Normal iron studies.

Requested Tests : VBF*, TFT, MBA, LIP, FE, FBE, A1C*

79 BALONNE ST, NARRABRI. 2390

Phone: 0473925904 **Birthdate:** 10/09/1998 Sex: M Medicare Number: 2457747468 Your Reference: 00072079 Lab Reference: 23-24481926-LIP-0

Laboratory: Laverty Pathology

Addressee: DR JULIAN WHITE Referred by: DR JULIAN WHITE

Name of Test: LIPID STUDIES (LIP-0)

Requested: 04/10/2023 **Collected:** 04/10/2023 **Reported:** 04/10/2023

LIPID STUDIES

Specimen Type: Serum

Reference intervals are included for reference only, and interpretation / treatment goals should be guided by patient-specific cardiovascular risk assessment (see Australian Cardiovascular Risk Charts. Alternatively, the web-site www.cvdcheck.org.au can be accessed in order to complete a risk assessment for individual patients.)

Haemolysis Nil Icterus Nil Lipaemia Nil

Fasting status Random

Total Cholesterol 5.3 mmo1/L (3.0-5.2)

NVDPA TARGET LIPID RANGES (MMOL/L) FOR PATIENTS AT HIGH / MODERATE RISK OF CARDIOVASCULAR DISEASE:

TOTAL CHOLESTEROL	<4.0
TRIGS (FASTING)	<2.0
HDL-C	>= 1.0
LDL-C	<2.0
NON HDL-C	<2.5

Requested Tests: VBF*, TFT, MBA, LIP, FE, FBE, A1C*

79 BALONNE ST, NARRABRI. 2390

Phone: 0473925904 Birthdate: 10/09/1998 Sex: M Medicare Number: 2457747468 Your Reference: 00072079 Lab Reference: 23-24481926-A1C-0

Laboratory: Laverty Pathology

Addressee: DR JULIAN WHITE Referred by: DR JULIAN WHITE

Name of Test: GLYCATED HAEMOGLOBIN (A1C-0)

Requested: 04/10/2023 Collected: 04/10/2023 Reported: 04/10/2023

23.41

GLYCATED HAEMOGLOBIN (HBA1c)

Specimen Type: EDTA

HbA1c- NGSP 5.2 (4.0-6.0)HbA1c- IFCC 33 mmol/mol (20-42)

The WHO recommends that an HbA1c cut-off of >=6.5% (48 mmol/mol) is used to diagnose type 2 diabetes.

While it is recognised that HbAlc levels approaching this cut-off place patients at increasingly higher risk of developing diabetes (<6.5%), there is no consensus as to exactly which cut-off at the lower end of the continuum to use for categorising patients as high risk. Various groups quote lower limits for at-risk patients that vary between 5.5% and 6.0% (37 and 42 mmol/mol).

Please note that HbAlc should not be used for diagnosing diabetes mellitus in the following circumstances:

- Children and young people
- Pregnancy current or within the past 2 months
- Suspected Type 1 diabetes mellitus
- Symptoms of diabetes for <2 months
- Patients who are acutely ill
- Patients taking drugs that can cause rapid onset hyperglycaemia such as corticosteroids, antipsychotic drugs
 - Acute pancreatic damage or pancreatic surgery
- Kidney failure
- Patients being treated for HIV infection

Please be cautious when requesting or interpreting HbAlc when patients:

- May have an abnormal haemoglobin
- May be anaemic
- May have an altered red cell lifespan (e.g. post-splenectomy)
- May have had a recent blood transfusion

Requested Tests: VBF*, TFT, MBA, LIP, FE, FBE, A1C

79 BALONNE ST, NARRABRI. 2390

Phone: 0473925904 Birthdate: 10/09/1998 Sex: M Medicare Number: 2457747468 Your Reference: 00072079 Lab Reference: 23-24481926-VBF-0

Laboratory: Laverty Pathology

Addressee: DR JULIAN WHITE Referred by: DR JULIAN WHITE

Name of Test: B12, FOLATE, R.C.FOLATE (VBF-0)

Requested: 04/10/2023 Collected: 04/10/2023 **Reported:** 04/10/2023

23:59

VITAMIN B12 AND FOLATE STUDIES

Vitamin B12		pmol/L	(301-740)
Active B12		pmol/L	(> 40)
Serum Folate	> 54.0	nmol/L	(> 9.0)

Serum Vitamin B12 Assay:

DEFICIENCY	BORDERLINE	SUFFICIENCY
<150 pmol/L	150 - 300 pmol/L	>300 - 740 pmol/L

For patients with total B12 levels in the low or borderline range, testing for active B12 (holotranscobalamin II) will automatically be performed to resolve B12 status. Active B12 is the biologically active fraction of total serum B12, and a superior indicator of B12 status. Up to 15% of individuals may have a deficiency of the carrier protein haptocorrin, which does not result in clinical B12 deficiency, despite low total B12 levels.

Serum Active B12 Assay:

This active B12 result indicates that the patient is likely to be vitamin B12 sufficient. Patients with renal impairment may still be B12 depleted despite an active B12 level within this range. For these patients, correlation with total B12, homocysteine and/or methylmalonate is required.

Folate Interpretation:

			~~~~~
	DEFICIENCY		SUFFICIENCY
Serum Folate:	<4.5 nmol/L	4.5 - 9.0 nmol/L	>9.0 nmol/L
RBC Folate:		340 - 570 nmol/L	>570 nmol/L

## Serum Folate Assay:

In the absence of recent oral intake, a serum folate >9.0~nmol/Leffectively rules out folate deficiency.

Red cell folates (RCF) are no longer processed routinely. If you have requested a RCF, and require a result for appropriate clinical reasons. this will need to be discussed and agreed with a Consultant Haematologist on +61290027085 or Dr. Lucinda Wallman, Consultant Pathologist in Immunology and Medical Director on telephone number +61 290057179

Requested Tests: VBF, TFT, MBA, LIP, FE, FBE, A1C